Antiangiogenic agents can alleviate immunosuppression, enabling CD8+ T cells to access the tumor tissue by relieving endothelial anergy and increasing adhesion molecule expression, thus augmenting checkpoint blockade activity [46,47]. The gene discussed is CD8A; the disease is neoplasm.